Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Genocea Biosciences (GNCA)

Genocea Biosciences (GNCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 109,959
  • Shares Outstanding, K 54,435
  • Annual Sales, $ 1,360 K
  • Annual Income, $ -43,710 K
  • 60-Month Beta 1.63
  • Price/Sales 81.71
  • Price/Cash Flow N/A
  • Price/Book 62.71
Trade GNCA with:

Options Overview

Details
  • Implied Volatility 160.24%
  • Historical Volatility 38.09%
  • IV Percentile 48%
  • IV Rank 37.36%
  • IV High 321.49% on 05/11/21
  • IV Low 64.09% on 03/12/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 16
  • Volume Avg (30-Day) 554
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 7,243
  • Open Int (30-Day) 7,598

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.19
  • Number of Estimates 3
  • High Estimate -0.18
  • Low Estimate -0.19
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +26.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.92 +5.44%
on 07/27/21
2.34 -13.68%
on 07/01/21
-0.32 (-13.68%)
since 06/30/21
3-Month
1.92 +5.44%
on 07/27/21
2.72 -25.74%
on 05/03/21
-0.58 (-22.31%)
since 04/30/21
52-Week
1.80 +12.22%
on 11/10/20
4.05 -50.06%
on 02/16/21
-1.43 (-41.45%)
since 07/30/20

Most Recent Stories

More News
Genocea Biosciences: Q2 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Genocea Biosciences Inc. (GNCA) on Thursday reported a loss of $4.3 million in its second quarter.

GNCA : 2.02 (-0.98%)
Genocea Provides Second Quarter 2021 Corporate Update

GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues

GNCA : 2.02 (-0.98%)
Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update conference...

GNCA : 2.02 (-0.98%)
Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug

Genocea Biosciences (GNCA) doses the first patient in phase I/IIa study on its investigational neoantigen-targeted T-Cell therapy, GEN-011, for solid tumors

TBIO : 27.64 (-22.38%)
GNCA : 2.02 (-0.98%)
CTLT : 119.81 (+0.41%)
ADXN : 9.85 (+8.24%)
Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy

Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the dosing of the first patient in its TiTAN study, a Phase...

GNCA : 2.02 (-0.98%)
Is the Options Market Predicting a Spike in Genocea (GNCA) Stock?

Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.

GNCA : 2.02 (-0.98%)
Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021

Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 vaccination was 15 months

GNCA : 2.02 (-0.98%)
Genocea Biosciences (GNCA) Reports Q1 Loss, Misses Revenue Estimates

Genocea Biosciences (GNCA) delivered earnings and revenue surprises of 15.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

GNCA : 2.02 (-0.98%)
Genocea Biosciences: Q1 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Genocea Biosciences Inc. (GNCA) on Thursday reported a loss of $12 million in its first quarter.

GNCA : 2.02 (-0.98%)
Genocea Provides First Quarter 2021 Corporate Update

GEN-011 and GEN-009 immuno-oncology programs continue to advance

GNCA : 2.02 (-0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections,...

See More

Key Turning Points

3rd Resistance Point 2.08
2nd Resistance Point 2.06
1st Resistance Point 2.04
Last Price 2.02
1st Support Level 2.00
2nd Support Level 1.98
3rd Support Level 1.96

See More

52-Week High 4.05
Fibonacci 61.8% 3.19
Fibonacci 50% 2.92
Fibonacci 38.2% 2.66
Last Price 2.02
52-Week Low 1.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar